Inflammation in neurodegenerative disease - A double-edged sword

Neuron

Volumn 35, Issue 3, 2002, Pages 419-432

  Wyss Coray, Tony ^a   Mucke, Lennart ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACCUMULATION; CONFORMATION; DEGENERATIVE DISEASE; HUMAN; INFLAMMATION; MOLECULAR BIOLOGY; NERVE CELL NETWORK; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

EID: 0036685522     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(02)00794-8     Document Type: Review

References (176)

1. Anti-inflammatory therapy for Alzheimer's disease: Implications of the prednisone trial
2. Inflammation and Alzheimer's disease
3. Transgenic expression of IFN-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration
4. Glial responses to synaptic damage and plasticity
5. Immune reactivity in a mouse model of familial ALS correlates with disease progression
6. Cytokines and acute neurodegeneration
7. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice
8. Pathogeneic role of autoantibodies in neurological diseases
9. Imaging of amyloid-beta depositis in brains of living mice permits direct observation of clearance of plaques with immunotherapy
10. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
11. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism
12. The free radical theory of aging matures
13. Immunological aspects of microglia: Relevance to Alzheimer's disease
14. Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in Rasmussen's encephalitis
15. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
16. Neuronal plasticity and cellular immunity: Shared molecular mechanisms
17. Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide
18. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia
19. The immunological synapse
20. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors
21. Novel role of human CD4 molecule identified in neurodegeneration
22. C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice
23. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6
24. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
25. TGF-β released by apoptotic T cells contributes to an immunosuppresive milieu
26. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders
27. Regulation of Class I MHC gene expression in the developing and mature CNS by neural activity
28. Apoptosis in Alzheimer disease
29. Prospects for neurology and psychiatry
30. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcipts
31. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis
32. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat
33. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture
34. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
35. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
36. Brain plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease
37. Human CD14 mediates recognition and phagocytosis of apoptotic cells
38. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease
39. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease
40. Imaging T-cell antigen recognition and comparing immunological and neuronal synapses
41. Reduced levels of amyloid β-peptide antibody in Alzheimer's disease
42. Molecular profile of reactive astrocytes - Implications for their role in neurologic disease
43. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones
44. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils
45. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF
46. A receptor for phosphatidylserine-specific clearance of apoptotic cells
47. Evolutionary perspectives on amyloid and inflammatory features of Alzheimer's disease
48. TGF-β1 is an organizer of responses to neurodegeneration
49. Complement and apoptosis
50. + T cells in peripheral blood
51. Characterization of microglia and macrophages in the central nervous system of rats: Definition of the differential expression of molecules using standard and novel monoclonal antibodies in the normal CNS and in four models of parenchymal reaction
52. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils
53. Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid
54. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa
55. Complement components of the innate immune system in health and disease in the CNS
56. An appetite for apoptotic cells? Controversies and challenges
57. Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages
58. Mostly dead
59. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila
60. The effects of a novel NSAID on chronic neuroinflammation are age dependent
61. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome
62. Apoptosis: Corralling the corpses
63. Basic principles of immunological surveillance of the normal central nervous system
64. Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans
65. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis
66. Complement
67. Functional requirement for Class I MHC in CNS development and plasticity
68. Autoantibodies to amyloid-beta in Alzheimer's disease
69. HLA-DQ7 antigen and resistance to variant CJD
70. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice
71. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
72. Murine models of brain aging and age-related neurodegenerative diseases
73. Disturbances in the peripheral T-cell repertoire of patients with motor neuron disease: High levels of activation and indirect evidence of superantigen
74. Immunologic reactions in amytrophic lateral sclerosis brain and spinal cord tissue
75. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation?
76. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response
77. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum
78. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: Tissue entry and local retention of antigen-specific B cells
79. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene
80. Microglia: A sensor for pathological events in the CNS
81. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function
82. Activated immune system in patients with Huntington's disease
83. Gene-expression profile of the ageing brain in mice
84. 3 on astrocytes and triggers formation of focal contact sites
85. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
86. Expression of MHC class I and β2-microglobulin in rat spinal motoneurons: Regulatory influences by IFN-gamma and axotomy
87. Expression of MHC class I heavy chain and β2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons
88. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family
89. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis
90. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond
91. Quantitative synaptic alterations in the human neocortex during normal aging
92. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
93. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
94. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells
95. Inflammation of the brain in Alzheimer's disease: Implications for therapy
96. Polymorphisms in inflammatory genes and the risk for Alzheimer disease
97. Ractive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
98. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
99. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes
100. Chemokines and chemokine receptors in the CNS: A possible role in neuroinflammation and patterning
101. Eine neue Entzündungstheorie. Entzündung und intrazelluläre Verdauung
102. Complement-dependent clearance of apoptotic cells by human macrophages
103. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
104. Immune hyporesponsiveness to amyloid β-peptide in amyloid presursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease
105. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
106. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction
107. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
108. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3
109. Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type
110. Complement anaphylatoxin receptors on neurons: New tricks for old receptors?
111. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: Differential regulation by interferon (IFN)-γ and tumor necrosis factor (TNF)-α
112. Innate immunity: The missing link in neuroprotection and neurodegeneration?
113. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells
114. Reversing neurodegeneration: A promise unfolds
115. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity
116. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
117. Mechanisms of MHC class I-restricted antigen processing
118. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor
119. Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions
120. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions
121. Molecular mechanisms of brain aging and neurodegenerative disorders: Lessons from dietary restriction
122. Abortive apoptosis in Alzheimer's disease
123. Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomized mouse facial motor nucleus and aggregate around sites of neuronal degeneration
124. Phagocytosis promotes programmed cell death in C. elegans
125. 2
126. Complement activation by β-amyloid in Alzheimer disease
127. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity
128. Apoptosis and the nervous system
129. Corpse clearance defines the meaning of cell death
130. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
131. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
132. The remedy may lie in ourselves: Prospects for immune cell therapy in central nervous system protection and repair
133. Phagocytosis and clearance of apoptotic cells is mediated by MER
134. Alzheimer's disease: Genes, proteins, and therapy
135. Dosing in phase II trial of Alzheimer's vaccine suspended
136. Amyloid β protein (Aβ) removal by neuroglial cells in culture
137. Complement activation by neurofibrillary tangles in Alzheimer's disease
138. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative disease
139. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease
140. Complement and innate immunity
141. An alternative, nonapoptotic form of programmed cell death
142. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor
143. Risk of Alzheimer's disease and duration of NSAID use
144. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease
145. Exacerbation of damage and altered NF-KB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury
146. Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation
147. History of immunology. The birth of immunology. III. The fate of the phagocytosis theory
148. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo
149. C1q receptors: Regulating specific functions of phagocytic cells
150. Membrane receptors for soluble defense collagens
151. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
152. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
153. The 200-and150-kDa neurofilament proteins react with IgG autoantibodies from patients with Kuru, Creutzfeldt-Jakob disease, and other neurologic diseases
154. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease
155. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis
156. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study
157. Immunosuppressive effects of apoptotic cells
158. The cerebral proteopathies - Neurodegenerative disorders of protein conformation and assembly
159. Capture and processing of exogenous antigens for presentation on MHC molecules
160. Aggregation state-dependent activation of the classical complement pathway by the amyloid β peptide
161. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
162. Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q
163. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
164. The complex of microglial cells and amyloid star in three-dimensional reconstruction
165. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
166. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
167. Autoimmunity and neurological disease: Antibody modulation of synaptic transmission
168. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease
169. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
170. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
171. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins
172. Cellular cofactors for amyloid β-peptide-induced cell stress. Moving from cell culture to in vivo
173. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients
174. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
175. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence
176. Phylogenetic aspects of the complement system